Millennium Pharmaceuticals has appointed three members to its executive management team: chief scientific officer Joseph Bolen, Ph.D., chief medical officer Nancy Simonian, M.D., and senior vice president of non-clinical development sciences Peter Smith, Ph.D. Together they will lead the company’s R&D efforts.

“The skill, experience and passion that Joe, Nancy and Pete bring to their jobs are unequaled in the industry. Together, they will continue to drive our efforts of bringing new medicines to patients,” says Deborah Dunsire, M.D., president and chief executive officer of Millennium.

Dr. Bolen joined the company in 1999 to lead oncology discovery efforts. In 2002 he was appointed senior vice president of discovery, and named chief scientific officer in 2006. Prior to joining the company, he held positions with Hoechst Marion Roussel, DNAX Research Institute of Molecular and Cellular Biology, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Institutes of Health.

Dr. Simonian joined the company in 2001 to lead clinical development efforts, and in 2006 was named chief medical officer. She is responsible for all clinical, regulatory, pharmacovigilance and development project management functions at the company. Prior to joining the company, she held a clinical research position at Biogen. She was previously an assistant clinical professor of neurology at Massachusetts General Hospital and Harvard Medical School.

Dr. Smith joined the company in 2001 as senior vice president of preclinical development and was named senior vice president of non-clinical development sciences in 2006. He oversees preclinical development for all discovery and development programs. Prior to joining the company, he held positions at Smithkline, Merck, Pharmacia and Searle/Monsanto.